The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro ...

A new study showed that semaglutide may help with alcohol use disorder Cara Lynn Shultz is a writer-reporter at PEOPLE. Her work has previously appeared in Billboard and Reader's Digest.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It found that semaglutide, the substance in Ozempic and the weight loss ...

Feb. 13, 2025 – For years, some people taking the drug semaglutide to treat diabetes or obesity have reported not only eating less, but drinking less alcohol. The reports have prompted many to ...

Semaglutide could help people drink less alcohol. Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Ozempic (semaglutide) is an injectable medication initially designed to manage type 2 diabetes. Over the past few years, its potential to aid weight loss has captured more public attention.